|
|||||
|
|
| 多西紫杉醇联合吉西他滨治疗晚期非小细胞肺癌的近期疗效分析 | |
| 引用本文： | 胡晓璐,李高峰,王巍炜,杨秀梅,陈楠. 多西紫杉醇联合吉西他滨治疗晚期非小细胞肺癌的近期疗效分析[J]. 中国医疗前沿, 2009, 0(3): 11-12 |
| 作者姓名： | 胡晓璐 李高峰 王巍炜 杨秀梅 陈楠 |
| 作者单位： | [1]昆明医学院第三临床附属医院放疗科,云南昆明650118 [2]昆明医学院第三临床附属医院胸外科,云南昆明650118 |
| 基金项目： | 基金项目：本项目受云南省教育厅基金资助,基金编号07y10569. |
| 摘 要： | 目的观察了解多西紫杉醇联合吉西他滨治疗晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。方法42例Ⅲ～Ⅳ期NSCLC患者均经病理组织学和（或）细胞学检查确诊。多西紫杉醇联合吉西他滨治疗后评价疗效。结果42例患者均可评价，获得CR3例，PR16例，有效率45.2%（19/42）。最主要的毒副反应为白细胞及血小板降低，但均可耐受。生存质量较前改善。结论西紫杉醇联合吉西他滨治疗晚期NSCLC有较好疗效，可明显改善患者生存质量，，毒副反应轻，易于耐受。 |
| 关 键 词： | 非小细胞肺癌 多西紫杉醇 吉西他滨 化疗 |
Clinical observation of Gemcitabine and Docetaxel Combinations in treating advanced non-small cell lung cancer |
|
| Affiliation: | Huxiaolu, Ligaofeng, Wangweiwei ,Yangxiumei,Chengnan (Dept of Chest Surgery, The 3rd Affiliated Hospital of Kunming Medical College, Kunming 650118, China) |
| Abstract: | Objective To evaluate the clinical effect and toxieity of Gemcitabine and Docetaxel Combinations in treating advanced non-small cell lung cancer（NSCLC ）.Methods 42 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study. The patients received and were evaluated effect after 2-4 cycles. Results Complete remisson （CR） was observrd in 3 cases and PR in 16 cases, the total response rate was 45.2% （19/42）. The main side effects were leucopenia and thrombocytopenia, but they were tolerable. Conclusion The regimen of Gemcitabine and Docetaxel is effective, safe and well-tolerable in the treatment of advanced NSCLC. |
| Keywords: | NSCLC Gemcitabine Docetaxel Chemotherapy |
| 本文献已被 维普 等数据库收录！ | |